QRxPharma Ltd., of Sydney, Australia, said additional data from the Phase III trial of MoxDuo IR (morphine/oxycodone) showed the drug reduced the risk of severe oxygen desaturation compared to morphine or oxycodone alone. A new drug application filing is slated for later this year.